RISK OF STING POST VENOM IMMUNOTHERAPY

本子项目是利用由NIH/NCRR资助的中心赠款提供的资源的众多研究子项目之一。子项目和研究者（PI）可能已经从另一个NIH来源获得了主要资金，因此可以在其他CRISP条目中表示。列出的机构是中心的，不一定是研究者的机构。以前有报道说，当毒液免疫治疗在5年或更长时间后停止时，在停止治疗后的最初几年，刺痛反应的风险仍低于10%。一些研究者研究了仅在3年后停止治疗，但提出了限制条件，如患者较年轻、反应较轻、治疗期间刺痛挑战阴性或RAST阴性。这项研究的结果将显示患者是否可以安全地在3年后停止治疗，而不是我们目前推荐的5-6年，以及在停止治疗后的10年内，反应的风险是否仍然可以接受的低。此外，我们将确定治疗前反应史较轻的患者或皮肤试验阴性和/或RAST患者的风险是否较低。我们继续按照我们的计划，每年刺更多的病人。今年我们有1名患者参加了刺痛挑战，结果只是局部反应。结果再次证明了停止毒液免疫治疗后的良好结果。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. It has previously been reported that when venom immunotherapy is discontinued after 5 years or more, the risk of a sting reaction remains less than 10% in the first few years after stopping treatment. Some investigators have studied discontinuation of therapy after only 3 years, but have suggested restrictions such as younger patients, milder reactions, and negative sting challenge during therapy or negative RAST. The results of this study will show whether patients can safely stop therapy after only 3 years instead of our current recommendation of 5-6 years, and whether the risk of reaction remains acceptably low in the 10 years after stopping therapy. Also, we will determine whether there is a lower risk in those patients with a less severe history of reaction before treatment or in those who have developed negative skin tests, and/or RAST. We continue to follow our plan of stinging more patients each year. This year we had 1 patient participate in a sting challenge, resulting in a local reaction only. The result again continues to demonstrate the excellent outcome after discontinuing venom immunotherapy.